NASDAQConsumer DiscretionaryRestaurantsSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Annual ending 2026-12-31 | ||
| Revenue | — | 38.11M |
| EPS | — | 2 |
Management figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Capital raised through private placements | The company raised $21 million in private placements to fund growth. | Intact | capital raised falls below $10M in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stabilize leadership after executive changes | Management aims to stabilize leadership after recent executive changes. | Improving | More than one C-level executive leaves within 4 quarters | 0 C-level departures vs target 0 CEO bought stock; two new directors appointed to fill vacancies; no C-level departures reported. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth through strategic agreements | A primary condition in REBORN COFFEE INC's published investment case. The stated target is >=$5.21M revenue in 2026-Q1. | Intact | revenue falls below $3.5M in any quarter after 2026-Q1 | Revenue: $6.322M FY2026-Q2; GAAP. Published target: >=$5.21M revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Sep 14, 20266,321,843 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 071c9d6d-6cc9-4b02-a5fb-bcc57bd2452e. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextThe supplied transcripts do not assign fiscal periods to the agreement disclosures, so recurrence across transcript quarters cannot be established. Revenue was $5,211,447 in 2026-Q1 and $6,321,843 in 2026-Q2, while operating income was negative in both quarters. The Visvita release reports an initial $2 million purchase order against a $30 million first-year volume target, but no financial results for these orders are supplied; delivery against the new agreement is not yet demonstrated. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 18, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, high-risk business rather than an established compounder, with weak recent performance and volatile management. The multi-year view is at a watch stage, and the recent signal has shifted from cautious to mixed.
The valuation evidence describes REBN as cheap versus peers, but the expectations gap is negative and model confidence is medium. The priced-in assessment is labeled justified, with no fragility gates triggered, though the evidence does not specify what particular business outcomes the market assumes.
Revenue rose from the first to the second quarter of 2026, but operating losses widened, and the business remained loss-making. A new agreement includes an initial purchase order and a first-year volume target, but delivery and financial results are not yet demonstrated; the latest supplied events also report Nasdaq notices and a late filing.
The key company-specific test is whether strategic agreements produce delivered orders and revenue while losses improve, and whether REBN makes substantive progress on listing compliance. Near term, guidance cuts would add pressure, while results and guidance from consumer-discretionary bellwethers could strengthen or weaken the sector backdrop.
Over the next 1 to 3 years, the thesis depends on execution, improving financial performance, and resolving compliance concerns; current evidence remains mixed and the risk is high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.